Clinical outcomes of chronic kidney disease patients treated with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES)

BackgroundThe target lesion revascularization of paclitaxel-eluting stents (PES) has been reported to be lower than that of sirolimus-eluting stents in patients on hemodialysis (HD). However, the comparison of PES and second generation drug-eluting stents in CKD patients has not been fully investigated. We compared clinical outcomes of everolimus-eluting stents (EES) and PES in CKD patients.MethodsHundred and forty seven CKD patients (eGFR < 60 mL min−1 1.73 m−2) treated with PES (n = 74, from May 2007 to December 2009) and EES (n = 73, from January 2010 to January 2013) were enrolled in the study. Major adverse cardiac events (MACEs) were defined as death, non-fatal myocardial infarction, and ischemia driven target lesion revascularization.ResultsThe incidence of 36-month MACE was significantly lower in EES, non-HD group compared to PES, non HD group (0% in EES group and 13.5% in PES group, respectively, P < 0.01). There was no significant difference in MACE between EES and PES in HD patients (5.4% in PES group and 5.5% in EES group, P = 0.98). In multivariate analysis, PES group and PES ISR were independent factors for worse incidence of MACE.ConclusionsIn CKD patients, PES was associated with worse clinical outcomes in non-HD patients as compared with EES.